



inven2

WE TURN RESEARCH AND KNOWLEDGE INTO PRODUCTS AND SERVICES THAT BENEFIT SOCIETY

Inven2 is a limited company owned by the University of Oslo (UiO) and Oslo University Hospital (OUH). Highly capable researchers and clinicians from UiO, OUH and many other Norwegian hospitals report their innovative research results to us. We evaluate these research results, and proceed to develop the ones that can be transformed into products and services that benefit society.

We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licenses are in the field of life science, since our ecosystem is especially strong in that field.

inven2

Email: post@inven2.com

Web: www.invento.com



A list of our current licensing opportunities is presented below.

Therapeutics:

- Novel therapy for currently untreatable hypertension
 - A potent and specific small molecule tankyrase inhibitor
 - Compounds for ROS-powered PDT without external light (onepager available upon request)
 - TANDEMAB: IgA-IgG fusions with tailored effector functions
 - An optimized engineered albumin for half-life extension and mucosal delivery of biologics
 - A versatile improved antibody Fc technology platform
 - Novel applications of VAS for treatment and prevention of cardiorenal damage in HFpEF
 - siRNA drug targeting MTHFD2 for treatment of prostate cancer
 - HLA-II targeting vaccines
 - Tuned CAR-T cells – a platform technology
 - CAR-T for p95HER2-positive breast cancer patients resistant to HER2 antibody treatments
 - STEAP1 CAR for metastatic prostate cancer
 - CAR T-cell Therapy for Osteosarcoma (OSCAR)
 - Dual CAR T-cell targeting CD19/Ig-kappa for safer Lymphoma therapy
-

In vitro diagnostics:

- Biomarker for de-escalating adjuvant chemotherapy in breast cancer.
 - A urine test for detection and monitoring of bladder cancer
 - Prediagnostic RNA biomarkers for early detection of lung cancer
-

Medical devices and eHealth:

- Multilumen glaucoma surgery stent
 - Early detection of brain-tumor progression
 - Non-Invasive Diagnostic Tool for Heart Failure
 - AI-based segmentation of vascular structures
 - Faster and better image processing in radar, sonar and ultrasound
 - A neural network based denoising system
-

Other technology:

- Rapeseed trait reducing seed loss
- Bio-engineered palladium nanoparticles
- Scalable Pump-less organ-on-a-chip platform with directed flow
- Very high production rates of medical radio isotopes with cyclotrons
- Sensitive CHIP-seq method for the study of single cells and small pools of cells